Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Denali Therapeutics (DNLI) EBITDA (2017 - 2026)

Denali Therapeutics has reported EBITDA over the past 9 years, most recently at -$129.0 million for Q4 2025.

  • Quarterly EBITDA fell 9.05% to -$129.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$513.9 million through Dec 2025, down 21.95% year-over-year, with the annual reading at -$513.9 million for FY2025, 21.95% down from the prior year.
  • EBITDA was -$129.0 million for Q4 2025 at Denali Therapeutics, down from -$126.7 million in the prior quarter.
  • Over five years, EBITDA peaked at $184.5 million in Q2 2023 and troughed at -$133.0 million in Q1 2025.
  • The 5-year median for EBITDA is -$99.7 million (2024), against an average of -$84.8 million.
  • Year-over-year, EBITDA soared 398.4% in 2023 and then tumbled 154.42% in 2024.
  • A 5-year view of EBITDA shows it stood at -$77.2 million in 2021, then decreased by 21.33% to -$93.7 million in 2022, then fell by 26.11% to -$118.2 million in 2023, then fell by 0.07% to -$118.3 million in 2024, then decreased by 9.05% to -$129.0 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's EBITDA are -$129.0 million (Q4 2025), -$126.7 million (Q3 2025), and -$125.2 million (Q2 2025).